Aspirin Use Improves Survival in Patients with Inoperable Non–Small-Cell Lung Cancer

Web Exclusives —January 25, 2022

Categories:

Lung Cancer

In 2020, lung cancer was the leading cause of cancer death, accounting for 18% of all cancer deaths. Lung cancer also represents 11.4% of all cancer diagnoses, with non–small-cell lung cancer (NSCLC) accounting for the majority of cases of lung cancer. Approximately 65% of patients with NSCLC are initially diagnosed with locally advanced or metastatic disease that conveys a poor prognosis despite aggressive treatment. These poor patient outcomes demonstrate an ongoing need to develop effective treatments for NSCLC.

Recently, there has been renewed interest in repurposing aspirin for cancer treatment. Aspirin inhibits cyclooxygenase enzymes, which promote carcinogenesis via synthesis of prostaglandin. Aspirin also upregulates tumor-suppression genes, inhibits NF-kB activation, and may induce apoptosis, suppress angiogenesis, and inhibit cancer cell proliferation. A study of 700 patients with colorectal cancer demonstrated that the use of aspirin was associated with reducing the risk of developing cancer. Further epidemiologic studies have established an inverse association between aspirin use and the risk of cancer development. However, other clinical trials have demonstrated no association, and 1 study in elderly patients demonstrated an increased risk of cancer-related mortality. Similarly, in aspirin-use studies of patients with NSCLC, results have been unclear.

To help clarify if aspirin use benefits those with NSCLC, a population-based retrospective cohort study of 4979 adult patients between the ages of 18 and 90 years with inoperable NSCLC was performed and the results were published in BMC Cancer. This patient cohort used aspirin at the time of diagnosis and for >28 daily doses after diagnosis. Exclusion criteria included patients who received pulmonary surgery, patients treated with etoposide, and those patients with coexisting malignancies. The matched cohort group (n = 4932) did not use aspirin. The study’s primary objective was overall survival with a median follow-up time of 1.73 years for the aspirin cohort and 1.22 years for the non–aspirin-use cohort. For the aspirin cohort, the median time of aspirin use was 0.47 years with a mean of 0.88 ± 1.12 years. Aspirin users were more likely to be male, have comorbidities, and to be older. Aspirin users had a significant survival benefit, with a median overall survival of 1.73 years compared with 1.30 years for the non-aspirin users. This study did have several limitations. Information about patient histology and TNM staging was not available. Body mass index, smoking history, family history, exposure to environmental toxins, and details on chemotherapy and radiotherapy were also not available for analysis.

This study suggests that aspirin use in patients with inoperable NSCLC is associated with increased survival, but further research is necessary to confirm these findings.

Source

Chuang MC, Yang YH, Hsieh MJ, et al. The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. BMC Cancer. 2021;21:1257.

Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country